Julian Walter Holch1, Ingrid Ricard2, Sebastian Stintzing3, Dominik Paul Modest4, Volker Heinemann5. 1. Department of Medical Oncology, University Hospital Grosshadern, Ludwig-Maximilians-Universität München, Marchioninistrasse 15, 81377 Munich, Germany; Comprehensive Cancer Center, University Hospital Grosshadern, Ludwig-Maximilians-Universität München, Marchioninistrasse 15, 81377 Munich, Germany. Electronic address: julian.holch@med.uni-muenchen.de. 2. Institute of Medical Informatics, Biometry, and Epidemiology, Ludwig-Maximilians-Universität München, Marchioninistrasse 15, 81377 Munich, Germany. Electronic address: ricard@ibe.med.uni-muenchen.de. 3. Department of Medical Oncology, University Hospital Grosshadern, Ludwig-Maximilians-Universität München, Marchioninistrasse 15, 81377 Munich, Germany; Comprehensive Cancer Center, University Hospital Grosshadern, Ludwig-Maximilians-Universität München, Marchioninistrasse 15, 81377 Munich, Germany. Electronic address: sebastian.stintzing@med.uni-muenchen.de. 4. Department of Medical Oncology, University Hospital Grosshadern, Ludwig-Maximilians-Universität München, Marchioninistrasse 15, 81377 Munich, Germany; Comprehensive Cancer Center, University Hospital Grosshadern, Ludwig-Maximilians-Universität München, Marchioninistrasse 15, 81377 Munich, Germany. Electronic address: dominik.modest@med.uni-muenchen.de. 5. Department of Medical Oncology, University Hospital Grosshadern, Ludwig-Maximilians-Universität München, Marchioninistrasse 15, 81377 Munich, Germany; Comprehensive Cancer Center, University Hospital Grosshadern, Ludwig-Maximilians-Universität München, Marchioninistrasse 15, 81377 Munich, Germany. Electronic address: volker.heinemann@med.uni-muenchen.de.
Abstract
BACKGROUND: Retrospective subgroup analyses suggest that primary tumour location (PTL) has a prognostic importance and relates to response to targeted therapy. METHODS: We conducted a meta-analysis of first-line clinical trials available up to October 2016, which assessed the relevance of PTL in patients with metastatic colorectal cancer (mCRC). Right- and left-sided colorectal cancers were differentiated (RC and LC). RESULTS: In 13 first-line randomised controlled trials and one prospective pharmacogenetic study, RC was associated with a significantly worse prognosis compared with LC (hazard ratio [HR] for overall survival: 1.56; 95% confidence interval [CI]: 1.43-1.70; P < 0.0001). A meta-analysis of PRIME and CRYSTAL study suggests that PTL was predictive of survival benefit from addition of anti-EGFR antibody to standard chemotherapy in patients with RAS wild-type tumour (overall survival, HR for LC: 0.69; 95% CI: 0.58-0.83; P < 0.0001 and HR for RC: 0.96; 95% CI: 0.68-1.35; P = 0.802). A meta-analysis of FIRE-3/AIO KRK0306, CALGB/SWOG 80405 and PEAK study indicates that patients with RAS wild-type LC had a significantly greater survival benefit from anti-EGFR treatment compared with anti-VEGF treatment when added to standard chemotherapy (HR 0.71; 95% CI: 0.58-0.85; P = 0.0003). By contrast, in patients with RC, benefit from standard therapy was poor and bevacizumab-based treatment was numerically associated with longer survival (HR 1.3; 95% CI: 0.97-1.74; P = 0.081). CONCLUSIONS: The present meta-analysis demonstrates that PTL is prognostic in mCRC. Further, it supports the conclusion that patients with left-sided RAS wild-type mCRC should be preferentially treated with an anti-EGFR antibody. In right-sided mCRC, chemotherapy plus bevacizumab is a treatment option, but optimal treatment has yet to be defined.
BACKGROUND: Retrospective subgroup analyses suggest that primary tumour location (PTL) has a prognostic importance and relates to response to targeted therapy. METHODS: We conducted a meta-analysis of first-line clinical trials available up to October 2016, which assessed the relevance of PTL in patients with metastatic colorectal cancer (mCRC). Right- and left-sided colorectal cancers were differentiated (RC and LC). RESULTS: In 13 first-line randomised controlled trials and one prospective pharmacogenetic study, RC was associated with a significantly worse prognosis compared with LC (hazard ratio [HR] for overall survival: 1.56; 95% confidence interval [CI]: 1.43-1.70; P < 0.0001). A meta-analysis of PRIME and CRYSTAL study suggests that PTL was predictive of survival benefit from addition of anti-EGFR antibody to standard chemotherapy in patients with RAS wild-type tumour (overall survival, HR for LC: 0.69; 95% CI: 0.58-0.83; P < 0.0001 and HR for RC: 0.96; 95% CI: 0.68-1.35; P = 0.802). A meta-analysis of FIRE-3/AIO KRK0306, CALGB/SWOG 80405 and PEAK study indicates that patients with RAS wild-type LC had a significantly greater survival benefit from anti-EGFR treatment compared with anti-VEGF treatment when added to standard chemotherapy (HR 0.71; 95% CI: 0.58-0.85; P = 0.0003). By contrast, in patients with RC, benefit from standard therapy was poor and bevacizumab-based treatment was numerically associated with longer survival (HR 1.3; 95% CI: 0.97-1.74; P = 0.081). CONCLUSIONS: The present meta-analysis demonstrates that PTL is prognostic in mCRC. Further, it supports the conclusion that patients with left-sided RAS wild-type mCRC should be preferentially treated with an anti-EGFR antibody. In right-sided mCRC, chemotherapy plus bevacizumab is a treatment option, but optimal treatment has yet to be defined.
Authors: Rona Yaeger; Walid K Chatila; Marla D Lipsyc; Jaclyn F Hechtman; Andrea Cercek; Francisco Sanchez-Vega; Gowtham Jayakumaran; Sumit Middha; Ahmet Zehir; Mark T A Donoghue; Daoqi You; Agnes Viale; Nancy Kemeny; Neil H Segal; Zsofia K Stadler; Anna M Varghese; Ritika Kundra; Jianjiong Gao; Aijazuddin Syed; David M Hyman; Efsevia Vakiani; Neal Rosen; Barry S Taylor; Marc Ladanyi; Michael F Berger; David B Solit; Jinru Shia; Leonard Saltz; Nikolaus Schultz Journal: Cancer Cell Date: 2018-01-08 Impact factor: 31.743
Authors: George Papaxoinis; Vassiliki Kotoula; Eleni Giannoulatou; Georgia-Angeliki Koliou; Vasilios Karavasilis; Sotirios Lakis; Andreas Koureas; Mattheos Bobos; Elpida Chalaralambous; Emily Daskalaki; Kyriakos Chatzopoulos; George Tsironis; Elisavet Pazarli; Sofia Chrisafi; Epaminontas Samantas; Ioannis G Kaklamanos; Ioannis Varthalitis; Athina Konstantara; Konstantinos N Syrigos; George Pentheroudakis; Dimitrios Pectasides; George Fountzilas Journal: Med Oncol Date: 2018-05-31 Impact factor: 3.064
Authors: Jonathan M Loree; Allan A L Pereira; Michael Lam; Alexandra N Willauer; Kanwal Raghav; Arvind Dasari; Van K Morris; Shailesh Advani; David G Menter; Cathy Eng; Kenna Shaw; Russell Broaddus; Mark J Routbort; Yusha Liu; Jeffrey S Morris; Rajyalakshmi Luthra; Funda Meric-Bernstam; Michael J Overman; Dipen Maru; Scott Kopetz Journal: Clin Cancer Res Date: 2017-11-27 Impact factor: 12.531
Authors: John M Creasy; Eran Sadot; Bas Groot Koerkamp; Joanne F Chou; Mithat Gonen; Nancy E Kemeny; Leonard B Saltz; Vinod P Balachandran; T Peter Kingham; Ronald P DeMatteo; Peter J Allen; William R Jarnagin; Michael I D'Angelica Journal: Ann Surg Oncol Date: 2017-11-27 Impact factor: 5.344